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Abstract
Background: The increased multi-omics information on carefully phenotyped patients in studies of complex
diseases requires novel methods for data integration. Unlike continuous intensity measurements from most omics
data sets, phenome data contain clinical variables that are binary, ordinal and categorical.
Results: In this paper we introduce an integrative phenotyping framework (iPF) for disease subtype discovery. A
feature topology plot was developed for effective dimension reduction and visualization of multi-omics data. The
approach is free of model assumption and robust to data noises or missingness. We developed a workflow to
integrate homogeneous patient clustering from different omics data in an agglomerative manner and then
visualized heterogeneous clustering of pairwise omics sources. We applied the framework to two batches of lung
samples obtained from patients diagnosed with chronic obstructive lung disease (COPD) or interstitial lung disease
(ILD) with well-characterized clinical (phenomic) data, mRNA and microRNA expression profiles. Application of iPF to
the first training batch identified clusters of patients consisting of homogenous disease phenotypes as well as
clusters with intermediate disease characteristics. Analysis of the second batch revealed a similar data structure,
confirming the presence of intermediate clusters. Genes in the intermediate clusters were enriched with
inflammatory and immune functional annotations, suggesting that they represent mechanistically distinct disease
subphenotypes that may response to immunomodulatory therapies. The iPF software package and all source codes
are publicly available.
Conclusions: Identification of subclusters with distinct clinical and biomolecular characteristics suggests that
integration of phenomic and other omics information could lead to identification of novel mechanism-based
disease sub-phenotypes.
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Background
Disease phenotyping refers to a procedure that specifies
disease definition or diagnosis in terms of observable ab-
normal phenotypic characteristics that occur due to the
interaction between genotypes and environmental ef-
fects. Traditionally, the two largest pulmonary disease
phenotypes—obstructive and restrictive lung disease-
s—have been determined using physiological, radio-
logical, or histopathological features. Our study focuses
on the most common diseases representing these afore-
mentioned phenotypes—COPD and ILD. COPD is a
lung disease caused by the repeated exposure to a nox-
ious agent resulting in irreversible airflow limitation.
COPD is classified by the Global Initiative for Chronic
Obstructive Lung Disease criteria in four major categor-
ies based on symptoms, airflow obstruction, and exacer-
bation history [1]. Similarly, the term Interstitial Lung
Disease designates a loosely defined group of patients
characterized by changes in the interstitium of the lung,
causing pulmonary restriction and impaired gas ex-
change. This group includes: Idiopathic Pulmonary Fi-
brosis (IPF), Non Specific Interstitial Pneumonia (NSIP),
Hypersensitivity Pneumonitis (HP), Cryptogenic Organ-
izing Pneumonia (COP), Respiratory Bronchiolotis-
associated Interstitial Lung Disease (RB-ILD), Collagen
Vascular Disease—associated Interstitial Lung Disease
(CVD-ILD), Desquamative Interstitial Pneumonia (DIP)
and Acute Interstitial Pneumonia (AIP), among others.
Despite the advancement in phenotyping these two
broad lung disease categories based on traditional
methods, current clinical definitions and classifications
of COPD or ILD often fail to accommodate the large
number of patients with atypical features who typically
fall into undefined categories [2]. Moreover, existing
classifications do not reflect advances in high-
throughput mRNA and miRNA expression techniques
that may improve our understanding of the complexity
of a given individual’s phenotype. In this paper, we refer
to “phenome” as the collection of traditional disease
phenotypes described above, which is in contrast to
measurements from rapidly developing high-throughput
omics techniques. The purpose of this paper is to pro-
vide a generalizable phenotyping procedure by combin-
ing phenome and other omics data (mRNA and miRNA
expression in our example) for novel disease subtype
discovery.
As the array and massively parallel sequencing costs
keep dropping, omics data generation has increased at
an unprecedented rate. Meaningful integration and pres-
entation of the abundant information has led to new
computational and statistical challenges. According to
Tseng et al. (2012) [3], omics data integration contains
two major categories: horizontal meta-analysis and verti-
cal integrative analysis. In the former type of data
integration, the same type of omics data sets (e.g. gene
expression, GWAS or eQTL) are collected from different
labs and aligned horizontally with gene features matched
on the rows. The major purpose of the analysis is similar
to traditional meta-analysis, repeated over all features on
the genome for candidate biomarker or pathway detec-
tion. In the latter analysis, multi-layers of omics data
(such as genotyping, gene expression, miRNA expres-
sion, methylation and mutations) are measured in a
given patient cohort and integrative analyses are per-
formed to understand the inter-omics disease mechan-
ism and relationship. As an example, the Cancer
Genome Atlas (TCGA) [4] contains multi-omics data for
more than 10,000 patients, and spans more than 20 can-
cers. Vertical information integration of multi-layer
omics data has gained increasing attention in the past
few years in biomedical research [5–8]. Depending on
biological purposes, many tools have been developed. A
large collection of existing integrative applications utilize
relatively naïve summary/comparative scores (e.g. corre-
lations and signal-to-noise ratios) and visualization tools
(e.g. heatmaps, scatter plots, volcano plots, box plots
and survival curves) with minimal statistical information
integration [9, 10] and several convenient packages or
pipelines along this approach are available [11, 12].
Other advanced statistical and computational methods
have been rapidly developed. For example, methods have
been developed to integrate copy number variation or
methylation with gene expression profiles [13, 14]. Di-
mension reduction methods including principal compo-
nent analysis [15], partial least squares [16], and
nonnegative matrix factorization [17] have been applied
to identify homogeneous and heterogeneous patterns
across multi-omics data. To identify novel disease sub-
types, the Bayesian consensus clustering [18] and iClus-
ter [19] are two recent powerful methods to combine
multi-omics data. They are, however, limited by a few
drawbacks that motivated the development of our new
integrative phenotyping framework (iPF). First, both
Bayesian consensus clustering and iCluster assume nu-
merical (continuous) measurements in the multi-omics
data but the complexity of phenome data that contains
binary, ordinal and multi-class categorical data types is
not addressed. Second, both methods are model-based
and poor performance is expected if the distribution as-
sumptions are violated. Finally, both methods lack
visualization tools for further exploratory analysis. The
proposed iPF described in this paper aims to fill these
gaps. iPF incorporates automatic feature selection, di-
mension reduction, data smoothing and pattern
visualization in the feature topology plot. Single-omic
cluster analysis is applied to each omics data set and a
workflow to encompass homogeneous and heteroge-
neous clustering information across omics data is
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performed. In our application to the COPD and ILD
data, novel disease subphenotypes were characterized
and validated by training and testing batches. Post-
hoc functional analysis revealed important biological
processes related to the disease subtypes that might
lead to novel diagnosis or treatment strategy. All data
sets and source code used in this paper are publicly
available as an iPF R package (http://tsenglab.biostat.
pitt.edu/software.htm).
Results
Overview of Integrative phenotyping framework (iPF)
The integrative phenotyping framework (iPF) consists of
the following four steps in the flowchart (Fig. 1): (1)
Data pre-processing: Each omics data set is adequately
pre-processed and normalized. Redundant (e.g. non-
expressed and/or non-informative) features are separ-
ately eliminated in each omics data set; (2) Feature con-
catenation: Omics data sets are vertically combined as in
Fig. 2a. A distance (dissimilarity) matrix between any
two features within and across omics data sets is defined
(Fig. 2b); (3) Dimension reduction: Multidimensional
scaling (MDS) is applied to map all features to a two-
dimensional Euclidean space for dimension reduction
(Fig. 2c); (4) Feature smoothing: Feature intensities are
smoothed in the reduced 2D space for each patient
(Fig. 2d); (5) Clustering for subtype discovery and
visualization: Unsupervised clustering analysis is per-
formed to identify potential disease subtypes, and feature
intensities within each cluster are averaged to generate
representative plots for each cluster (Fig. 2e). The result-
ing contour plots are referred to as “feature topology
plots (FTP)”, hereafter. Details of the iPF framework are
presented in the method section and supporting
information.
Different omics data may contribute to similar (homo-
geneous) or distinct (heterogeneous) disease subtype
definition. For example, iCluster vertically aligns multi-
omics data and performs latent variable decomposition.
It implicitly assumes that different omics data contribute
to one final and common disease subtype definition. The
Bayesian consensus clustering method alternatively
models common and distinct patient subtypes from dif-
ferent omics data. In our framework, we perform pair-
wise agglomerative merging strategy when a pair of
omics data sets present “homogeneous” clustering re-
sults. For example, when three omics data sets (mRNA,
microRNA (miRNA) and clinical) are available in Fig. 3,
all pairs of omics data sets are compared. If mRNA and
miRNA generate similar clustering results while the
other two pairs do not, we merge mRNA and miRNA.
Finally, we compare the clustering results of mRNA +
miRNA versus clinical. This strategy can be generalized
to combining three or more omics data sets and system-
atically but dynamically investigate clusters identified in
different omics data. To determine homogeneity or het-
erogeneity of clustering results, Fig. 4 shows the feature
topology plots for clusters from the first and the second
omics data sources on the left and on the top (three
clusters in each omics data source). The number of over-
lapped patients in the 3 × 3 table provides evidence of
homogeneity (majority of patients are on the diagonal;
for example, mRNA vs miRNA in Additional file 1:
Figure S8(a)) or heterogeneity (existence of clusters
off-diagonal as shown in Additional file 1: Figure
S8(a), (b) and Fig. 4).
Discovery of disease subtypes from multi-omics data sets
In this study, we combine three omics data sets (669
clinical variables, 4258 mRNA expressions and 438
miRNA expressions) from a cohort of 319 lung disease
patients. To estimate the number of clusters, Additional
file 1: Figure S9A-D presents the Gap statistics and the
incremental differences in each omics data set for differ-
ent comparisons. Almost all of the results clearly indi-
cate 3 clear clusters in each omics data sources.
Additional file 1: Figure S8 shows feature topology plots
of the pairwise comparison of clustering results from
each omics data set. The pie charts of the clusters de-
scribe the composition of existing diagnoses from clini-
cians. The three clusters identified from mRNA data and
miRNA data are highly consistent with only 38 off-
diagonal samples (38/319 = 12 %), while the comparison
Fig. 1 Flow chart of Integrative Phenotyping Framework (iPF):
Integrative phenotyping framework (iPF) includes the following
steps (1) Data preprocessing (2) Feature concatenation (3)
Dimension reduction (4) Feature smoothing (5) Clustering for
subtype discovery and visualization
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of mRNA vs clinical and miRNA vs clinical show hetero-
geneous clustering with 121 (38 %) and 150 (47 %) off-
diagonal samples (Additional file 1: Figure S8). As a
result, we merge mRNA and miRNA data for combined
cluster analysis and compare with the clustering result
from the clinical data in Fig. 4. The result shows three
consensus clusters (cluster A, 76 samples mostly COPD;
cluster I, 80 samples mostly ILD; cluster E, 43 samples
of intermediate subtype) and six off-diagonal differen-
tially defined clusters from the two omics data sources.
Noticeably, 18 samples (cluster G) are determined ILD-
like from clinical data but are viewed as COPD-like from
mRNA +miRNA clustering. Similarly, 11 samples (clus-
ter C) are viewed as COPD-like in clinical clustering but
Fig. 2 Overview of integrative clustering in integrative phenotyping framework (iPF): (a) Vertically combined multiple omics data sets (b) A
distance matrix between any two features within and across omic data sets (c) Multidimensional scaling (MDS) mapping to a two-dimensional
Euclidean space (d) Smoothed feature intensities in the reduced 2D space for each patient (e) Unsupervised clustering to identify potential
disease subtypes and averaged feature intensities for representative plots of each cluster
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are ILD-like in mRNA +miRNA clustering. COPD and
ILD are considered to have distinct disease mechanisms
because of their extremely divergent phenotypic patterns
despite similar risk factors as well as the presence of a
combined emphysema and pulmonary fibrosis overlap-
ping syndrome [20]. This makes it possible that omics
measurements might help improve disease phenotyping.
For example, the diagnoses of the first cluster (n = 121)
by clinical data (sum of cluster A, B, and C) are mostly
associated with COPD. With additional information
from mRNA and miRNA expression, these 121 samples
are further divided into clusters A, B and C. Overall, the
result shows the limitation of current disease diagnosis
that can be improved by large-scale clinical and
transcriptomic measurements. The identified cluster E
(and potentially also clusters B, D, F and H) may present
a novel intermediate disease subtype with a disease
mechanism different from existing COPD and ILD
definitions.
A common issue in using omics data sets for disease
subtype discovery is the reproducibility and potential
presence of batch effects. To validate the finding, our
analysis initially started with a first training cohort of 91
patients and was then validated in a second testing co-
hort of 228 patients. The proposed comprehensive valid-
ation scheme is comprised of the three phases of
discovery, prediction and validation. A first training co-
hort produces clustering and MDS coordinates results,
Fig. 3 Graphical illustration of heterogeneous data sets comparison scheme in iPF. Step 1-2: Compare and combine all possible pairs of omics
data sets until we produce homogenous clustering results. Step 3: Pairwise comparison until identifying any heterogeneous data sets
Fig. 4 iPF clustering results for multiple omics data sets using all samples (Clinical, mRNA +miRNA). This figure shows three clusters are
generated in each omics data source, and the feature topology plots for clusters from the first and the second omics data sources on the left
and on the top, respectively
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and thereby the MDS coordinates are directly applied to
the testing cohort for clustering as the prediction phase.
In the validation phase, clustering results are produced
within the testing cohort. In our analysis, clustering re-
sults in the prediction and the validation phase show
high reproducibility with a consistently identified inter-
mediate disease subtype (see Additional file 1: Figure S6).
Additional file 1: Figure S6(a) demonstrates a workflow of
three phases of discovery, prediction and validation.
Additional file 1: Figure S6(b) demonstrates the discovery
phase of clustering results from the training cohort. The
model is then applied to the testing cohort for clustering
as the prediction phase in Additional file 1: Figure S6(c).
Additional file 1: Figure S6(d) shows a validation phase of
clustering result within the testing cohort. By comparing
Additional file 1: Figure S6(c) and (d), the result shows
high reproducibility with a consistently identified inter-
mediate disease subtype. To analytically measure a level of
concordance between clusters in Fig. 2c and d, we employ
adjusted rand index (ARI) [21]. The estimated ARIs are
0.764 for the clinical data set and 0.43 for the three clus-
ters in the transcriptomic data set (mRNA+miRNA).
Taken together, we conclude that the discovered clusters
from the training and testing cohort preserve common
characters, which enable the combination of all the sam-
ples (n = 319) from the three batches in the pooled ana-
lysis, as shown in Fig. 4.
Discovery of discriminant phenome features
We focus our analysis on the three consistent clusters,
hereafter referred to as Cluster A, E and I. Table 1 shows
the group means of 12 selected demographic and clinical
variables for the three clusters and their pairwise as well
as overall ANOVA p-values. Patients in cluster E were
likely to be younger (average age 55 years) when com-
pared to clusters A and I (65.7 and 66.1 years respect-
ively) and there were more females (65.1 %) compared
to A and I (39.5 % and 30 % respectively). In contrast,
patients in cluster A had a more obstructive pattern in
their pulmonary function test (average FEV1/FVC ratio
0.653) compared to those in clusters E and I (0.93 and
1.12 respectively). Similarly, quantitative CT analysis re-
vealed that patients in cluster A were more likely to have
emphysema (CT% emphysema 14.4 %) while those in
cluster I were more likely to have high lung reticular vol-
umes (662 mL). In this case, patients in cluster E seemed
to express an intermediate phenotype although the gender
and age distributions do no suggest cluster E as a pure
intermediate phenotype between cluster A and I.
Gene co-expression modules and pathway analysis
demonstrates enrichment for inflammatory and immune
related annotations in Cluster E
We performed one-way ANOVA analysis for each
mRNA and miRNA feature based on cluster A (COPD),
E (Intermediate) and I (ILD) labels, and identified 1684
statistically significant (p-value adjusted by Bonferroni
< 1e-10) features in the gene expression (n = 1596) and
miRNA (n = 88). We further performed gene co-
expression cluster analysis using partition around
medoids (PAM) to identify four gene and miRNA mod-
ules in Fig. 5 (gap statistics analysis in Additional file 1:
Figure S10 clustered into four gene modules). Note that
we intentionally turned the 88 miRNAs to opposite dir-
ection (by multiplying the expression intensities by -1)
in the cluster analysis to account for the fact that most
miRNAs have inhibitory effects on mRNA expression.
As a result, expressions of miRNAs in a module [5] have
Table 1 Summary of significant features grouped in each cluster (cluster A, E, and I)a
Total Cluster A Cluster E Cluster I P-value Cluster Cluster Cluster
(n = 199) (n = 76) (n = 43) (n = 80) ANOVA A & E A & I E & I
Age, yrs 63.5 65.7 55 66.1 2.91E-07 7.68E–02 1.24E–07 5.05E–02
Gender, % female 41.2 39.5 65.1 30 7.51E–04 2.44E–02 7.23E–01 7.42E–04
Body Mass Index, BMI 28.6 28 27.5 29.8 3.29E–02 1.00E + 00 7.24E–02 1.07E–01
FEV1 % predicted 61.7 48 64.3 73.4 1.12E–13 4.37E–05 1.53E–13 3.61E–02
FVC % predicted 69.2 72.4 69.7 65.8 1.85E–02 1.00E + 00 1.79E–02 2.93E–01
FEV1/FVC ratio 0.9 0.653 0.93 1.12 3.62E–29 1.59E–09 1.49E–25 2.75E–09
DLCO 53.9 59.2 57.3 47 2.55E–03 1.00E + 00 8.14E–03 1.46E–02
Total lung capacity, mean 5.28 6.55 4.87 4.19 4.69E–19 1.16E–07 2.32E–18 4.98E–02
CT % emphysema 7.19 14.4 1.88 1.01 4.46E–13 1.73E–07 3.77E–11 3.70E–01
Lung reticular volume, ml 309 63.8 198 662 5.86E–17 2.22E–02 3.03E–16 2.32E–07
Diagnosis, % IPF 38.7 1.32 9.3 90 4.01E–33 1.16E–01 6.00E–28 6.75E–18
Diagnosis, % Emphysema 19.6 43.4 14 0 4.29E–11 3.20E–03 1.12E–10 1.99E–03
aThe average values of 12 selected demographic and clinical variables in each sub–cluster groups, p–values from Kruskal–Wallis ANOVA (all three groups) and
p-values from Kruskal-Wallis rank sum test (paired wise groups)
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a clear negative correlation with the remaining mRNAs
(blue) in Fig. 5.
In order to look more deeply into the biological path-
ways differentiating the microarray samples in cluster E
from those in cluster I (Fig. 5) we focused on the genes
in module two, since this was the most distinctive of all
studied modules. By using Ingenuity Pathway Analysis
(IPA, see Methods for more detail), we identified enrich-
ment for a large number of immune related annotations
in module two genes when comparing samples in cluster
E relative to those in cluster I. These annotations were
largely related to immune cell trafficking, predominantly
leukocyte activation, migration, movement and chemo-
taxis as well as cell movement of phagocytes, neutrophils
and myeloid cells (Additional file 1: Table S18). The
large majority of these annotations showed an increase
in their activation score (z-score), predicting the increase
activation of these functions in cluster E subjects.
Given the enrichment for immune related annotations,
we looked for potential drugs targeting overexpressed
genes in module two and identified drugs with immuno-
modulatory and immunosuppressive effects (Additional
file 1: Figure S12), medications that are currently not
recommended for the treatment of IPF patients, the pre-
dominant group of patients in cluster E. Some of these
drugs included hydroxichloroquine, a drug that has been
largely used to treat rheumatoid arthritis and systemic
lupus erythematous [22, 23]. Rituximab, a humanized
monoclonal antibody which targets B cell and is
commonly used to treat autoimmune disorders and
Efalizumab, a formerly available immunosuppressant
that was used to treat autoimmune disorders by inhibit-
ing lymphocyte activation and cell migration. Taken to-
gether, these results demonstrate how iPF allowed us to
identify a subset of patients with a predominant immune
related phenotype that could potentially respond to im-
munomodulatory therapy.
Simulation study to show advantages of iPF
To demonstrate that iPF is robust and accurate in dis-
ease subtype discovery using omics data, we simulated
data sets with various degrees of variances and propor-
tion of noise features, using the “clusterGeneration”
package. Additional file 1: Figure S11 shows that feature
fusion methods used in iPF (FF, FFspK and FFmClust)
outperform traditional clustering methods. More details
are shown in Additional file 1: Text S3.
Discussion
In this paper, we have proposed a framework to integrate
multi-omics data sources for disease subtype identifica-
tion. Compared to existing methods (such as iCluster
and Bayesian consensus clustering), iPF allows different
variable types (binary, continuous, ordinal and multi-
class), which are common in clinical variables. The
method is also model-free, manages missing values
Fig. 5 Heatmap for the four modules of gene expression and miRNA features which significantly differentiate three clusters (COPD, Intermediate,
and ILD). We performed gene co-expression cluster analysis using partition around modoids (PAM) to identify four gene and miRNA modules.
When perform clustering, the 88 miRNAs intensities are turned to the opposite direction (by multiplying the expression intensities by -1) to show
that most miRNAs have inhibitory effects on mRNA expression
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without imputation techniques (i.e., pair-wise feature
correlations can be estimated by excluding only samples
with missing values), robust to data noises and provides
effective visualization tools. Compared to the latent vari-
able estimation in iCluster and posterior distribution
simulation in Bayesian consensus clustering, the compu-
tational load of iPF is also much more affordable. Our
hierarchical integrative strategy (Fig. 3) further allows
analysis of homogeneous and heterogeneous clustering
structure across multi-omics data.
We tested the iPF framework using two large multi-
omic data sets obtained from lung tissues from well
characterized patients with chronic lung diseases. One
of the most relevant findings by iPF is the replication of
the two most distinct disease subphenotypes in pulmon-
ary medicine: COPD and ILD, diseases that represent
the opposite spectrum of lung physiologic patterns, air-
flow obstruction in COPD and lung restriction in ILD.
Currently, the diagnosis of obstructive and restrictive
lung diseases relies mostly on clinical findings, pulmon-
ary function test, radiologic studies and lung biopsies in
selected cases [24]. Results from genomic analyses of
lung tissues have not been included in diagnostic algo-
rithms in chronic lung diseases mostly because of the
added cost of these technologies, the difficulties to ac-
cess lung tissue samples and the concept that an accur-
ate diagnosis can be achieved by using the current
diagnostic armamentarium in clinical practice and most
commonly without the need to obtain a biopsy. Our
findings demonstrate that iPF is a valuable tool not only
because it was able to distinguish the known disease cat-
egories, but also because it allowed us to identify a pre-
viously unknown disease subphenotype of patients that
clustered in between patients with COPD and ILD (see
Additional file 1: Figure S19), characterized by the over-
expression of genes predominantly associated with im-
mune cell activation and trafficking. Interestingly, a large
number of patients in this cluster had the clinical diag-
nosis of Idiopathic Pulmonary Fibrosis (IPF).
The identification of genes associated with immune
cell activation in a subset of patients with IPF is relevant
for various reasons. IPF is a fibrotic lung disease of un-
known etiology, associated with high mortality rates
[25]. IPF is thought to be caused by repeated cycles of
alveolar epithelial cell injury followed by fibroblast re-
cruitment, proliferation and extracellular matrix depos-
ition [26]. In the past, IPF was considered to be a
chronic inflammatory process, in part, due to the partial
response observed with the use of immunosuppressive
therapy in a small subset of patients, evidence that was
limited to case reports [27]. Subsequently, a large ran-
domized, controlled clinical trial demonstrated that im-
munosuppressive drugs actually increased the mortality
and number of hospitalizations of IPF patients [28] and
the use of these drugs was abandoned from clinical prac-
tice. Our pathway analysis revealed enrichment for im-
mune related annotations when comparing samples
between intermediate (cluster E) and ILD (cluster I)
clusters (Fig. 4). These annotations were largely associ-
ated with immune cell trafficking, leukocyte activation,
migration, movement and chemotaxis (For details, see
Additional file 1: Table S18). The annotations mostly
present high activation scores suggesting increased acti-
vation of these pathways in cluster E patients. The fact
that some of the overexpressed genes in the intermediate
cluster of ILD patients are targeted by immonompodula-
tory drugs such as hydroxichloroquine, Rituximab, and
Efalizumab, suggest that a small subset of ILD patients,
even among those with idiopathic pulmonary fibrosis
(IPF), may actually benefit from immunomodulation. In
this regard, iPF facilitates sub-categorizing patients on
the basis of multi-level data sources beyond the conven-
tional diagnostic tools, and identifying biologically asso-
ciated functional annotations and new drugs effective to
the subset of patients, namely, implementing personal-
ized diagnosis and treatment of chronic lung diseases.
Integrative Phenotyping Framework has a few poten-
tial limitations. Firstly, the method applies dimension re-
duction and smooth techniques. The performance is
expected to deteriorate if the omics throughput is too
low (e.g. data from small number of clinical variables or
a small assay). Secondly, several procedures in iPF are
not fully automated and need expert decision. For ex-
ample, the decision of the number of clusters is not al-
ways easy and is an intrinsic methodological difficulty
for almost all clustering tools in real practice. In our
lung disease application, clusterings from mRNA and
miRNA were found to be almost identical and it was an
easy decision to merge the two omics data sets in the
hierarchical integration. In other applications, we expect
that deciding on the homogeneous or heterogeneous
clustering results may not always be clear-cut. Thirdly,
the hierarchical integration is performed pairwisely, mer-
ging and comparing two at a time. The number of clus-
ters may increase exponentially if many omics data sets
are combined and all omics data generate heterogeneous
clustering. However, such complexity may be an intrinsic
biological fact and cannot easily be accommodated by
statistical models. Finally, our findings in the first multi-
omics data set were only validated “in-silico” in the sec-
ond multi-omics data set. While it would have been
ideal to add a second validation method using an alter-
native gene expression platform (i.e. reverse transcript-
ase, polymerase chain reaction – qRT-PCR), we felt that
the strength of our results made unnecessary the
addition of an alternative validation method.
The integration of multi-omics data sources using the
iPF framework has immense potential to advance the
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field of personalized medicine by confirming clinical
diagnoses, aid in the identification of new disease sub-
phentoypes, provide biological insights, and new targets
for drug therapy. However, despite the impressive repro-
ducibility of our findings across two large data sets, add-
itional studies focusing on validating our results in other
large data sets will be required before the iPF framework
can be applied to daily clinical practice.
Methods
Integrative phenotyping framework (iPF)
Data pre-processing and feature integration
The overall workflow and diagram are demonstrated in
Figs. 1 and 2. For pre-processing, each omics data set
was normalized separately. Non-expressed (low mean in-
tensities) and non-informative (low standard deviations)
features were filtered. We consider the integration of M
different types of high-throughput omics data sets, de-
noting these by X mð Þ ¼ x mð Þij
n o
Im j jJj j
data set of the
mth omics, where xij
(m) is the intensity of feature i and
sample j for i ∈ Im, j ∈ J, and m = 1, 2, … , M. De-
note by ⇀X mð Þi ¼ x mð Þij ; … ; x mð Þi Jj j
n o
the feature vector
of the ith feature in the mth omics data set. The omics
data are vertically concatenated such that X = {xij}|I| × |J|
is the combined data set of all M data sets, where I = ∪
m = 1
MIm. (Fig. 2a). All features are standardized to have
zero mean and unit variance to avoid scaling issues or
dominance of certain omics types.
MDS dimension reduction and feature smoothing
Based upon the combined data set X, we calculate the
feature dissimilarity (distance) matrix by
D ¼
1f g I j jIj j−R
 
2
¼ dii′f g I j jIj j;
where R is the correlation matrix (defined in Additional
file 1: Table S14) between different variable types such
as continuous, ordinal, binary and multi-class categorical
(Fig. 2b). Multi-dimensional scaling (non-metric MDS)
is then applied to project all concatenated features onto
a two-dimensional space:
GX

X
⇀ðmÞ
i

¼ ðuðmÞi1 ; uðmÞi2 Þ; where GX : RJ →
R2 ; i ∈ Im and m ¼ 1; … ;M: Note that the
MDS mapping is performed based on the combined data
set X. MDS coordinates after feature projects are com-
parable across different omics data sets (Fig. 2c), an im-
portant property to allow clustering comparison across
omics data sets in a later step. Feature intensities are
represented by gradient color: red, yellow and blue
represent high, intermediate and low intensities re-
spectively. After dimension reduction, we apply a
nonparametric smoothing technique to intensities at
MDS coordinates using generalized additive model
(GAM) [29] and create a Feature Topology Plot (FTP)
using the smoothed intensities in 2D space (See
Additional file 1: Figure S5(b)). The smoothing method
applies a thin plate spline penalty as the basis (TPRS) [30].
It averages response values in a neighborhood and plays
an essential role for iPF to be robust against randomly
noisy features.
This workflow can be seen as converting integrated
feature vectors into a smoothed 2D image in the MDS
space, and includes multiple benefits. First, highly corre-
lated features are encouraged to concentrate in a small
region in the 2D image. So when we measure the dis-
tance (correlation) between two subjects based on 2D
space, these highly correlated feature will contribute less
than they do at the original feature space. It is challen-
ging to characterize high-dimensional covariance among
thousands or tens of thousands features. Instead we pro-
ject feature vectors into the 2D space (MDS), which help
to attenuate effects of highly correlated features. Second,
the smoothing technique reduces noise effects and thus
enhances the efficiency of clustering analysis. Additional
file 1: Text S3 presents various numerical simulations
for sensitivity and robustness analyses of the proposed
Feature Fusion technique (= Feature concatenation + Di-
mension reduction + Feature smoothing). Details of
smoothing and generation of Feature Topology Plots are
available in Additional file 1: Text S2.
Cluster analysis for subtype discovery and visualization
In Fig. 2 (d), we can generate the smoothed intensities of
each patient j in the mth omics data set. Suppose we
scale the MDS coordinates to the unit square (x, y coor-
dinates between 0 and 1). We represent the smoothed
intensity vector (of length (n + 1)2) of patient j in the mth
omics data set as c mð Þj ¼ f^ mð Þj sn ; tn
 n o
; where f^ mð Þj
s
n ;
t
n
 
is the smoothed intensity at the sn ;
t
n
 
MDS co-
ordinate (s = 0,1,…, n and t = 0,1,…,n). To perform clus-
ter analysis to assign patients into clusters based on the
mth omics data set, we adopt the dissimilarity measure
between any two patients i and j as Dj,j '
(m) = 1 − cor (cj
(m),
cj '
(m)), where cor(⋅,⋅) is the Pearson correlation of two
vectors. Partition around medoids (PAM) [31] is then
applied to cluster patients into potential disease sub-
types. The number of clusters is determined by Gap
statistics [32] for each omics data set. Figure 2e (Step
vii to viii) shows a schematic demonstration that
each of the two omics and clinical data sets gener-
ates three clusters of patients. One can further aver-
age the Feature Topology Plots in each cluster to
visually show the cluster patterns (Step ix in Fig. 2e).
For example, Additional file 1: Figure S8(a) shows
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almost identical cluster pattern visualization from
mRNA and miRNA expression data sets, which are
further validated by the confusion matrix with few
off-diagonal patients. This justifies combining mRNA
and miRNA for clustering and comparison with clus-
tering from the clinical data in Fig. 4.
Integrative strategy for multi-omics clustering
One major difficulty of disease subtype discovery using
multi-omics data is the possible heterogeneity of cluster-
ing results from different omics data. The above iPF
framework and visualization can handle integration of
M = 2 omics data sets. When M ≥ 3, we propose to first
compare all possible pairs of omics data sets (Fig. 3 Step
1). In our motivating example, three pairwise compari-
sons are demonstrated in Additional file 1: Figure S8. It
is clear that mRNA and miRNA gives almost the same
clustering results while clustering from clinical data is
very different from mRNA and miRNA. As a result, we
combine mRNA and miRNA (Fig. 3 Step 2) and com-
pare with clinical data (Fig. 3 Step 3) to generate the
final result shown in Fig. 4.
Biomarker detection and functional annotation
After patient clusters are determined from mRNA +
miRNA and clinical data clustering in Fig. 4, we select
the unambiguous clusters (cluster A: COPD; cluster I:
ILD; cluster E: novel intermediate subtype) for further
biomarker detection and functional annotation. One-
way analysis of variance [33] is applied to detect sig-
nificant biomarkers associated with the three clusters
(p-value adjusted by Bonferroni < 1e-10). The detected
biomarkers are clustered using partition around
medoids (PAM) to identify co-expressed gene mod-
ules and the number of gene modules is determined
by Gap statistics (Additional file 1: Figure S10). Func-
tional annotation is performed using Ingenuity Path-
way Analysis (IPA) software.
Methods for pathway enrichment analysis in cluster E
In order to identify underlying biological pathways dis-
tinguishing the microarray samples from patients in
cluster E relative to cluster I, we performed IPA and the
Ingenuity Downstream Effects Analysis. The down-
stream effects analysis is based on prior knowledge of
expected causal effects between genes and biological
functions stored in the Ingenuity® Knowledge Base. This
analysis examined genes in the selected modules that are
known to affect biological functions and compared their
direction of change (i.e. expression in cluster E samples
relative to cluster I) to that expected from the literature.
In this analysis, if the observed direction of change is
mostly consistent with a particular activation state of a
biological function (“increased” or “decreased”), then a
prediction is made about that activation state. For each
biological function, an activation z-score is computed.
The activation z-score is used to infer likely activation
states of biological functions based on comparison with
a model that assigns random regulation directions.
Conlusion
We present an integrative analysis tool to inter-connect
disease subphenotypes and visualize feature intensity
patterns. Using a large dataset of lung samples with par-
allel genomic and phenomic data, we show this integra-
tive phenotyping framework (iPF) can lead to successful
feature discovery and integrative clustering in high di-
mensional space. Applying iPF to large data sets, we
identify a subphenotype of patients with Chronic Ob-
structive Pulmonary Disease and Interstitial Lung Dis-
ease, characterized by overexpression of genes associated
with inflammatory and immune responses.
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